HK Stock Market Move | LAEKNA-B(02105) rose more than 7% during trading, previously announced excellent clinical data for the treatment of HR+/HER2- breast cancer in the Ib phase with LAE002.

LAEKNA-B (02105) rose more than 7% during trading hours, and as of the time of writing, it is up 2.81% at HK$4.75, with a trading volume of HK$1017.18 million. In terms of news, at the 2024 European Society for Medical Oncology (ESMO) Congress, Laike Pharmaceuticals announced the final data from the Phase Ib study of their innovative product LAE002 in combination with fluorouracil, for patients with advanced or metastatic HR+/HER2- breast cancer who have failed standard treatment. The median progression-free survival (PFS) in 18 breast cancer patients with PIK3CA/AKT1/PTEN mutations was 7.3 months. China Great Wall previously mentioned that the company's major catalysts in the second half of 2024 include releasing the Phase 1b clinical study data of LAE002 in combination with fluorouracil for the treatment of HR+/HER2- breast cancer in September, announcing the results of the Phase 1 exploratory study of LAE002 in combination with cetuximab and albumin-bound paclitaxel in October, and submitting an Investigational New Drug (IND) application for LAE120 (a USP1 target inhibitor) in Q4.